Evaluation of zinc effect on antibody titers of seasonal infiuenza vaccination in hemodialysis person.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201011245243N1

Enrollment

128

Registered

2011-01-03

Start date

2010-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza. Influenza and pneumonia

Interventions

Intervention 1: An injection of Trivalent influenza vaccine (VAXIGRIP) in deltoid muscle and zinc sulfate (50 mg/ daily/ for 30 days). Intervention 2: An injection of Trivalent influenza vaccine (VAXI

Prevention

Placebo

An injection of Trivalent influenza vaccine (VAXIGRIP) in deltoid muscle and zinc sulfate (50 mg/ daily/ for 30 days)

An injection of Trivalent influenza vaccine (VAXIGRIP) injection in deltoid muscle as well as placebo (sugar, one capsule /daily /for 30 days)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: hemodialysis person, serum antibody less than 1:40, absence of flu-like syndrome

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Immunity for Influenza Viruses. Timepoint: One month after Vaccination. Method of measurement: With Hemaglutination and Inhibition Method.	—

Secondary

Measure	Time frame
Adverse effect of vaccination. Timepoint: One Month. Method of measurement: Observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shaaban Shirzadi

Kermanshah University of Medical Sciences

Drshirzadi@kums.ac.ir www.heidarisohrab@yahoo.com A-Heiday@kums.ac.ir+98 83 1426 3264

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026